As a modular part of our nanocarrier system, siRNA can be designed and synthetized against any oncogenic factor and we here propose a targeted siRNA-transport system composed of an anti-CD33-antibody, protamine and siRNA that efficiently targets the leukemia-related oncogenes DNMT3A and FLT3. This evidence concerns the gene FLT3 and leukemia.